儿童急性白血病中的抗真菌药物使用:当前证据状况与未来研究方向
儿童白血病治疗中侵袭性真菌病(IFD)仍是常见严重并发症。本文由感染病与血液肿瘤专家小组基于2021年澳大利亚与新西兰真菌学抗真菌共识指南提出10个关键临床问题,通过聚焦文献综述梳理现有证据与知识缺口,以指导未来研究。
要点
- 儿童白血病IFD风险随治疗方案及阶段而异,抗真菌处方面临独特挑战。
- 成人大型临床试验与儿科药代动力学研究为儿童抗真菌优化提供越来越多数据。
- 全球IFD流行病学变化、白血病治疗演进及新药可及性使儿科临床研究倡导至关重要。
核心结论
- 全球IFD流行病学变化、儿科白血病治疗持续演进及新型抗真菌药物可及性增加,使倡导儿科临床研究对优化儿童白血病IFD预防和治疗至关重要。
研究设计与样本
- 感染病与血液肿瘤学专家小组在制定2021年澳大利亚与新西兰真菌学抗真菌共识指南后,提出10个关键临床问题并进行聚焦文献综述。
主要发现
- 儿童白血病抗真菌处方面临独特挑战,尤其因IFD风险在白血病治疗方案之间及方案内存在差异、药物毒性及抗真菌药与化疗药相互作用。
- 近期对IFD流行病学认识进展、成人评估抗真菌药治疗与预防IFD的大型临床试验及儿科临床与药代动力学研究,为儿童最佳抗真菌使用提供越来越多的数据。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Invasive fungal disease (IFD) remains a common and serious complication in children treated for leukaemia. Antifungal prescription in children with leukaemia presents unique challenges, particularly due to variation in IFD risk between and within leukaemia treatment protocols, drug toxicities and interactions between antifungals and chemotherapeutic agents. With recent advances in the understanding of IFD epidemiology and large clinical trials in adults assessing antifungals for IFD treatment and prophylaxis, together with paediatric clinical and pharmacokinetic studies, there is a growing body of data to inform optimal antifungal use in children. A panel of infectious diseases and haematology-oncology clinicians with expertise in IFD management compiled a list of 10 key clinical questions following development of the 2021 Australia and New Zealand Mycology Antifungal Consensus Guidelines. A focused literature review was conducted to explore available evidence and identify gaps in knowledge to direct future research. With the changing epidemiology of IFD globally, the ongoing evolution of paediatric leukaemia treatment and the increasing availability of novel antifungal agents, advocacy for paediatric clinical studies will remain vital to optimize IFD prevention and treatment in children with leukaemia.
引用
- Yeoh DK, Haeusler GM, McMullan BJ, et al. Antifungal use in children with acute leukaemia: state of current evidence and directions for future research. J Antimicrob Chemother. 2022. PMID: 35301533. doi:10.1093/jac/dkac060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。